It's all about leaving a legacy. That’s what Brad Branch said about establishing the Catherine S. and J. Bradford Branch Fund with his wife, Catherine Shingleton Branch. Through a generous estate gift to Duke, the couple has created an endowment to benefit both Duke Heart and Duke Cancer Institute (DCI).
The May family made it through a harrowing injury with help from plenty of Duke friends.
Most people understand the importance of team building, but few take it as seriously as Bob Keegan: building innovative and successful teams was the tenet of his professional career.
The Moore family marked dad Matthew’s 40th birthday with a special reunion following his artificial heart implant procedure. Duke Heart surgeons placed the first-in-North-America device in his chest July 12th.
When we get a cold, or a cut on our hand, we will heal. This concept of resilience is being studied and researched at Duke, and basic science research may hold many of the keys to unlocking the power of the human body to resist infection and disease.
A portable optical tool that promises to make surgical planning easier and less invasive for children who need surgery for epilepsy will get its first tests in the clinic, thanks to a $300,000 grant from The Hartwell Foundation.
For most cancers, advances in genomics haven’t changed treatment strategies very much. Sandeep Dave, MD, MS, envisions making personalized treatment a reality for more patients, by developing and making better use of tools that already exist.
The Duke Endowment of Charlotte, N.C., is supporting Duke University’s efforts to expand its faculty in computation, materials science and the resilience of the body and brain by completing the second phase of a $100 million investment.
A potential new vaccine developed by members of the Duke Human Vaccine Institute has proven effective in protecting monkeys and mice from a variety of coronavirus infections — including SARS-CoV-2 as well as the original SARS-CoV-1 and related bat coronaviruses that could potentially cause the next pandemic. The findings were published in the journal Nature.
Twin 9-year-old girls at Duke Health became the first in the United States to participate in a Pfizer and BioNTech Phase 1 study to evaluate safety, tolerability and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in preventing COVID-19 among healthy children below the age of 12.